Polyphor AG announced that its global Phase III study, FORTRESS, evaluating balixafortide in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint.
[Polyphor AG]
7992332
{7992332:nan}
apa
50
1
164029
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
